A clinical perspective of diabetic retinopathy

Geriatrics and Aging

Volumn 11, Issue 6, 2008, Pages 333-341

  Hudson, Chris ^a,b,c,d  

^a UNIVERSITY OF WATERLOO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Diabetic retinopathy; Laser photocoagulation; Macular edema; Neovascularization; Vision loss

Indexed keywords

EID: 49749092680     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Canadian Diabetes Association. Diabetes facts. The Association, 2005-2008; www.diabetes.ca/Section_About/Factslndex.asp. Accessed June 20, 2008.
2. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the doomsday scenario be averted? J Intern Med 2000;247:301-10.
3. Health Canada. Diabetes, complications. In: Diabetes in Canada, 2nd edition. Ottawa: Health Canada; 2003; www.phacaspc.gc.ca/publicat/dicdac2/ english/13chap1_e.html. Accessed June 16, 2008.
4. McIntosh D, Kjernisted K, Hammond J. Diabetes and depression: what is the association between these common, chronic illnesses? Can Diabetes 2008;21:3-7.
5. Voruganti LP, Parker G. Diabetes and mental health: new frontiers, challenges and opportunities. Can Diabetes 2006;21:8-9.
6. Health Canada. Use of health services and costs. In: Diabetes in Canada, 2nd edition. Ottawa: Health Canada; 2003; www.phacaspc.gc.ca/publicat/dicdac2/ english/36chap5_e.html. Accessed June 16, 2008.
7. Taylor R, Agius L. The biochemistry of diabetes. Biochem J 1988;250:625-40.
8. Kaji Y, Usui T, Ishida S, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007;48:858-65.
9. Wong TY, Rosamond W, Chang PP, et al. Retinopathy and risk of congestive heart failure. JAMA 2005;293:63-9.
10. Cheung N, Rogers S, Couper DJ, et al. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke 2007;38:398-401.
11. Collins VR, Dowse GK, Plehwe, et al. High prevalence of diabetic retinopathy and nephropathy in Polynesians of Western Samoa. Diabetes Care 1995;18:1140-9.
12. Moss SE, Klein R, Klein BEK, et al. Retinal vascular changes and 20-year incidence of lower extremity amputations in a cohort with diabetes. Arch Intern Med 2003;163:2505-10.
13. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am 2004;88:1001-36.
14. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995;113:36-51.
15. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
16. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: prospective observational study (UKPDS 36). BMJ 2000;321:412-9.
17. Kahn HA, Hiller R. Blindness caused by diabetic retinopathy. Am J Ophthalmol 1974;78:58-67.
18. Ross SA, McKenna A, Mozejko S, et al. Diabetic retinopathy in native and normative Canadians. Exp Diabetes Res 2007;2007:76271.
19. Canadian National Institute for the Blind National Office. CNIB Client Database. Toronto: The Institute; 2002.
20. International Diabetes Federation. Fact sheet diabetes and eye disease. www.idf.org/home/index.cfm?node=1155.
21. World Health Organization. What are common consequences of diabetes? 2006: www.who.int/mediacentre/factsheets/fs312/en/. Accessed June 20, 2008.
22. Brassard P, Robinson E, Dumont C. Descriptive epidemiology of non-insulin-dependent diabetes mellitus in the James Bay Cree population of Quebec, Canada. Arctic Med Res 1993;52:47-54.
23. Dannenbaum D, Kuzmina E, Lejeune P, et al. Prevalence of diabetes and diabetes-related complications in First Nations communities in Northern Quebec (Eeyou Istchee), Canada. Can J Diabetes 2008;32:46-52.
24. Archer DB. Bowman lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations. Eye 1999;13:497-523.
25. Gardner TW, Antonetti DA, Barber AJ, et al. and the Perm State Retina Research Group. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47:S253-62.
26. Wilkinson CP, Ferris FL III, Klein RE, et al. and the Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677-82.
27. Grading diabetic retinopathy from stereoscopic color fundus photographs. An extension of the modified Airlie House classification. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:786-806.
28. Olk RJ, Lee CM. Classification of diabetic retinopathy. In: Papadopoulos D, ed. Diabetic Retinopathy, Practical Management. Philadelphia: JB Lippincott Company; 1993:2-20.
29. Bresnick GH. Nonproliferative diabetic retinopathy. In: Ryan SJ, ed. Retina, 2nd edition (Vol. II). St. Louis: Mosby; 1994:1277-318.
30. Kinyoun J, Barton F, Fisher M, et al. and the EDTRS. Detection of diabetic macular edema. Ophthalmoscopy versus photography (ETDRS report no. 5). Ophthalmology 1989;96:746-51.
31. Hudson C, Flanagan JG, McLeod D. A clinical vision science perspective of the management of diabetic macular oedema. Excerpta Medica. Focus on Diabetic Retinopathy 2001;8:4-9.
32. Olk RJ, Lee CM. Indications for fluorescein angiography in the management of diabetic retinopathy. In: Papadopoulos D, ed. Diabetic Retinopathy, Practical Management. Philadelphia: JB Lippincott Company; 1993:129-39.
33. Bresnick GH, Condit R, Syrjala S, et al. Abnormalities of the foveal avascular zone in diabetic retinopathy. Arch Ophthalmol 1984;102:1286-93.
34. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy (ETDRS report no. 12). Ophthalmology 1991;98:823-33.
35. Olk RJ, Lee CM. Management of proliferative diabetic retinopathy. In: Papadopoulos D, ed. Diabetic Retinopathy, Practical Management. Philadelphia: JB Lippincott Company; 1993:85-114.
36. Olk RJ, Lee CM. Special cases. In: Papadopoulos D, ed. Diabetic Retinopathy, Practical Management. Philadelphia: JB Lippincott Company; 1993:157-81.
37. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy (ETDRS report no. 22). Arch Ophthalmol 1996;114:1079-84.
38. Aiello LP, Cahill MT, Wong JS. Perspective. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001;132:760-76.
39. Warpeha KM, Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003;17:305-11.
40. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV Diabetic macular edema. Ophthalmology 1984;91:1464-74.
41. Klein R, Moss SE, Klein BEK, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. The incidence of macular edema. Ophthalmology 1989;96:1501-10.
42. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14 year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology 1998;105:1799-815.
43. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is less 30 or more years. Arch Ophthalmol 1984;102:527-32.
44. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema (ETDRS report no. 1). Arch Ophthalmol 1985;103:1796-806.
45. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy (DRS report no. 8). Ophthalmology 1981;88:583-600.
46. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-62.
47. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55.
48. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-85.
49. Ogata N, Matsuoka M, Matsuyama K, et al. Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab 2007;92:1176-9.
50. Canadian Diabetes Association clinical practice guidelines. The Association, 2003; www.diabetes.ca/cpg2003/chapters.aspx. Accessed June 20, 2008.
51. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 2000;23:1084-91.
52. Sinclair SH. Diabetic retinopathy: the unmet needs for screening and a review of potential solutions. Expert Rev Med Devices 2006;3:301-13.
53. Fong AY, Wachman E. Hyperspectral imaging for the life sciences. In: Biophotonics International. Photonic Solutions for Biotechnology and Medicine, 2008:38-41.
54. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy (ETDRS report no. 9). Ophthalmology 1991;98:766-85.
55. Davies EG, Petty RG, Kohner EM. Long term effectiveness of photocoagulation for diabetic maculopathy. Eye 1989;3:764-7.
56. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005;89:74-80.
57. Olk RJ, Lee CM. Indications for vitrectomy. In Papadopoulos D, ed.: Diabetic Retinopathy, Practical Management. Philadelphia: JB Lippincott Company; 1993:115-27.
58. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-35.